Neoadjuvant FOLFIRINOX and IMRT concurrent with FDR-gemcitabine in patients with borderline resectable pancreatic cancer (BRPC).

被引：1
|
作者：
Tran, Nguyen H.
Sahai, Vaibhav
Griffith, Kent A.
Nathan, Hari
Kaza, Ravi
Cuneo, Kyle Clifford
Sonnenday, Christopher J.
Cho, Clifford
Lawrence, Theodore Steven
Zalupski, Mark
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Hlth Syst, Ann Arbor, MI USA
[3] Univ Massachusetts, Mem Med Ctr, Ann Arbor, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.381
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
381
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients
    Huang, Xiaolun
    Knoble, Jeanna L.
    Zeng, Ming
    Aguila, Fernando N.
    Patel, Tara
    Chambers, Lowell W.
    Hu, Honglin
    Liu, Hao
    PLOS ONE, 2016, 11 (12):
  • [12] FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
    Dhir, Mashaal
    Zenati, Mazen S.
    Hamad, Ahmad
    Singhi, Aatur D.
    Bahary, Nathan
    Hogg, Melissa E.
    Zeh, Herbert J., III
    Zureikat, Amer H.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (07) : 1896 - 1903
  • [13] FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
    Mashaal Dhir
    Mazen S. Zenati
    Ahmad Hamad
    Aatur D. Singhi
    Nathan Bahary
    Melissa E. Hogg
    Herbert J. Zeh
    Amer H. Zureikat
    Annals of Surgical Oncology, 2018, 25 : 1896 - 1903
  • [14] PROGNOSTIC FACTORS FOR PATIENTS WITH BORDERLINE RESECTABLE OR LOCALLY ADVANCED PANCREATIC CANCER RECEIVING NEOADJUVANT FOLFIRINOX
    Choi, Young Hoon
    Lee, Sang Hyub
    You, Min Su
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2019, 156 (06) : S321 - S322
  • [15] Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
    Tran, Nguyen H.
    Sahai, Vaibhav
    Griffith, Kent A.
    Nathan, Hari
    Kaza, Ravi
    Cuneo, Kyle C.
    Shi, Jiaqi
    Kim, Edward
    Sonnenday, Christopher J.
    Cho, Clifford S.
    Lawrence, Theodore S.
    Zalupski, Mark M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (01): : 124 - 133
  • [16] Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
    Choi, Jin G.
    Nipp, Ryan D.
    Tramontano, Angela
    Ali, Ayman
    Zhan, Tiannan
    Pandharipande, Pari
    Dowling, Emily C.
    Ferrone, Cristina R.
    Hong, Theodore S.
    Schrag, Deborah
    Fernandez-Del Castillo, Carlos
    Ryan, David P.
    Kong, Chung Yin
    Hur, Chin
    ONCOLOGIST, 2019, 24 (07): : 945 - 954
  • [17] Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
    Choi, Young Hoon
    Lee, Sang Hyub
    You, Min Su
    Shin, Bang Sup
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Kwon, Wooil
    Jang, Jin-Young
    Kim, Sun-Whe
    GUT AND LIVER, 2021, 15 (02) : 315 - 323
  • [18] Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC)
    Blazer, Marlo A.
    Wu, Christina Sing-Ying
    Goldberg, Richard M.
    Phillips, Gary S.
    Schmidt, Carl Richard
    Muscarella, Peter
    El-Dika, Samer S.
    Walker, Jon P.
    Krishna, Somashekar Gopala
    Groce, J. Royce
    Wuthrick, Evan John
    Williams, Terence M.
    Efries, David
    Smith, Yahna T.
    Mathey, Kris
    Wagner, Mandy
    Reardon, Josh
    Ellison, Edwin Christopher
    Bloomston, Mark
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [19] Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
    Choi, Yoo Jin
    Byun, Yoonhyeong
    Kang, Jae Seung
    Kim, Hyeong Seok
    Han, Youngmin
    Kim, Hongbeom
    Kwon, Wooil
    Oh, Do-Youn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Ryu, Ji Kon
    Kim, Yong-Tae
    Lee, Kyungbun
    Kim, Haeryoung
    Chie, Eui Kyu
    Jang, Jin-Young
    GUT AND LIVER, 2021, 15 (03) : 466 - 475
  • [20] Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
    Janssen, Quisette P.
    O'Reilly, Eileen M.
    Van Eijck, Casper H. J.
    Groot Koerkamp, Bas
    FRONTIERS IN ONCOLOGY, 2020, 10
12345